---
document_datetime: 2025-12-02 06:23:22
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/exparel-liposomal.html
document_name: exparel-liposomal.html
version: success
processing_time: 0.1126602
conversion_datetime: 2025-12-26 18:40:12.936932
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Exparel liposomal

[RSS](/en/individual-human-medicine.xml/67365)

##### Authorised

This medicine is authorised for use in the European Union

bupivacaine Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Exparel liposomal](#news-on)
- [More information on Exparel liposomal](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Exparel liposomal is a local anaesthetic that is used to treat pain after certain operations. It can be used in adults and children aged 6 years or older for local pain relief by injecting it around the edges of small to medium-sized surgical wounds. It is also used in adults for regional pain relief by injecting it around the nerves that supply the lower limbs or the shoulder. Exparel liposomal contains the active substance bupivacaine.

Expand section

Collapse section

## How is Exparel liposomal used?

Exparel liposomal is injected either around the edges of small to medium-sized surgical wounds or around the nerve supplying the operation site in the leg or shoulder area. The dose depends on the size of the operation site and the area that needs to be numbed, and the patient's physical condition.

Exparel liposomal should be given in a setting where trained personnel and appropriate resuscitation equipment are available to promptly treat patients in case they develop side effects of the heart and nervous system.

The medicine can only be obtained with a prescription. For more information about using Exparel liposomal, see the package leaflet or contact your doctor or pharmacist.

## How does Exparel liposomal work?

The active substance in Exparel liposomal, bupivacaine, is an anaesthetic that temporarily numbs the area to which it has been applied by blocking pain signals to the brain.

Bupivacaine has been available since the 1960s. In Exparel liposomal, it is enclosed in 'liposomes' (tiny fat particles) which release bupivacaine slowly.

## What benefits of Exparel liposomal have been shown in studies?

Four studies in 703 adults have shown that Exparel liposomal is effective at reducing pain scores when used for local pain relief around small to medium sized surgical wound sites and for regional pain relief in the surgery of the knee and around the shoulders.

For local pain relief, patients given Exparel liposomal after an operation for haemorrhoids (piles) had a total pain score for a 3-day period of 142, compared with 203 for patients given placebo (a dummy treatment). In patients who had an operation to remove bunions, the total pain score for a 1-day period was 124 for Exparel liposomal compared with 146 for placebo.

For regional pain relief, patients given Exparel liposomal after knee replacement operation had a total pain score for a 3-day period of 419, compared with 516 for patients given placebo. In patients who had a shoulder joint replacement operation, the total pain score for a 2-day period was 136 for Exparel liposomal compared with 254 for placebo.

In one main study, 65 children from 6 to 16 years of age undergoing spine or cardiac surgery received Exparel liposomal. The study showed that the way Exparel liposomal is absorbed, modified and removed from the body is similar in children and adults. Based on these data, it can be concluded that at the dose tested, Exparel liposomal will have comparable effects across these age groups when used for local pain relief around small to medium-sized surgical wound sites.

## What are the risks associated with Exparel liposomal?

The most common side effects with Exparel liposomal (which may affect more than 1 in 20 people) in adults are dysgeusia (taste disturbances) and oral hypoaesthesia (reduced sensation in the mouth). In children, anaemia (low levels of red blood cells), hypotension (low blood pressure), tachycardia (rapid heartbeat), vomiting, constipation, nausea, pruritus (itching) and muscle twitching may occur in more than 1 in 10 people.

The most important serious side effects are convulsions (fits), serious dysrhythmia (irregular heartbeat), serious hypotension (low blood pressure) and cardiac arrest.

Exparel liposomal must not be used in patients who are hypersensitive (allergic) to any of the ingredients of the medicine or to other local anaesthetics with a chemical structure related to the active ingredients (amide-type local anaesthetics). It must not be used as paracervical block anaesthesia (local anaesthetic injected at the top of the vagina) and must not be given by injection into a blood vessel or a joint.

For the full list of restrictions, see the package leaflet.

## Why is Exparel liposomal authorised in the EU?

The European Medicines Agency decided that Exparel liposomal's benefits are greater than its risks and it can be authorised for use in the EU. Studies showed that Exparel liposomal was effective at managing pain after different surgical procedures. The safety profile was considered acceptable.

## What measures are being taken to ensure the safe and effective use of Exparel liposomal?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Exparel liposomal have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Exparel liposomal are continuously monitored. Side effects reported with Exparel liposomal are carefully evaluated and any necessary action taken to protect patients.

## Other information about Exparel liposomal

Exparel liposomal received a marketing authorisation valid throughout the EU on 16 November 2020.

Exparel liposomal : EPAR - Medicine overview

Reference Number: EMA/781370/2022

English (EN) (144.14 KB - PDF)

**First published:** 10/12/2020

**Last updated:** 14/11/2022

[View](/en/documents/overview/exparel-liposomal-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-218)

български (BG) (168.64 KB - PDF)

**First published:**

10/12/2020

**Last updated:**

14/11/2022

[View](/bg/documents/overview/exparel-liposomal-epar-medicine-overview_bg.pdf)

español (ES) (143.97 KB - PDF)

**First published:**

10/12/2020

**Last updated:**

14/11/2022

[View](/es/documents/overview/exparel-liposomal-epar-medicine-overview_es.pdf)

čeština (CS) (167.01 KB - PDF)

**First published:**

10/12/2020

**Last updated:**

14/11/2022

[View](/cs/documents/overview/exparel-liposomal-epar-medicine-overview_cs.pdf)

dansk (DA) (142.7 KB - PDF)

**First published:**

10/12/2020

**Last updated:**

14/11/2022

[View](/da/documents/overview/exparel-liposomal-epar-medicine-overview_da.pdf)

Deutsch (DE) (147.2 KB - PDF)

**First published:**

10/12/2020

**Last updated:**

14/11/2022

[View](/de/documents/overview/exparel-liposomal-epar-medicine-overview_de.pdf)

eesti keel (ET) (131.93 KB - PDF)

**First published:**

10/12/2020

**Last updated:**

14/11/2022

[View](/et/documents/overview/exparel-liposomal-epar-medicine-overview_et.pdf)

ελληνικά (EL) (167.93 KB - PDF)

**First published:**

10/12/2020

**Last updated:**

14/11/2022

[View](/el/documents/overview/exparel-liposomal-epar-medicine-overview_el.pdf)

français (FR) (145.23 KB - PDF)

**First published:**

10/12/2020

**Last updated:**

14/11/2022

[View](/fr/documents/overview/exparel-liposomal-epar-medicine-overview_fr.pdf)

hrvatski (HR) (165.23 KB - PDF)

**First published:**

10/12/2020

**Last updated:**

14/11/2022

[View](/hr/documents/overview/exparel-liposomal-epar-medicine-overview_hr.pdf)

italiano (IT) (142.76 KB - PDF)

**First published:**

10/12/2020

**Last updated:**

14/11/2022

[View](/it/documents/overview/exparel-liposomal-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (182.28 KB - PDF)

**First published:**

10/12/2020

**Last updated:**

14/11/2022

[View](/lv/documents/overview/exparel-liposomal-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (166.65 KB - PDF)

**First published:**

10/12/2020

**Last updated:**

14/11/2022

[View](/lt/documents/overview/exparel-liposomal-epar-medicine-overview_lt.pdf)

magyar (HU) (165.58 KB - PDF)

**First published:**

10/12/2020

**Last updated:**

14/11/2022

[View](/hu/documents/overview/exparel-liposomal-epar-medicine-overview_hu.pdf)

Malti (MT) (167.48 KB - PDF)

**First published:**

10/12/2020

**Last updated:**

14/11/2022

[View](/mt/documents/overview/exparel-liposomal-epar-medicine-overview_mt.pdf)

Nederlands (NL) (143.47 KB - PDF)

**First published:**

10/12/2020

**Last updated:**

14/11/2022

[View](/nl/documents/overview/exparel-liposomal-epar-medicine-overview_nl.pdf)

polski (PL) (167.6 KB - PDF)

**First published:**

10/12/2020

**Last updated:**

14/11/2022

[View](/pl/documents/overview/exparel-liposomal-epar-medicine-overview_pl.pdf)

português (PT) (144.19 KB - PDF)

**First published:**

10/12/2020

**Last updated:**

14/11/2022

[View](/pt/documents/overview/exparel-liposomal-epar-medicine-overview_pt.pdf)

română (RO) (163.13 KB - PDF)

**First published:**

10/12/2020

**Last updated:**

14/11/2022

[View](/ro/documents/overview/exparel-liposomal-epar-medicine-overview_ro.pdf)

slovenčina (SK) (167.29 KB - PDF)

**First published:**

10/12/2020

**Last updated:**

14/11/2022

[View](/sk/documents/overview/exparel-liposomal-epar-medicine-overview_sk.pdf)

slovenščina (SL) (163.96 KB - PDF)

**First published:**

10/12/2020

**Last updated:**

14/11/2022

[View](/sl/documents/overview/exparel-liposomal-epar-medicine-overview_sl.pdf)

Suomi (FI) (142.16 KB - PDF)

**First published:**

10/12/2020

**Last updated:**

14/11/2022

[View](/fi/documents/overview/exparel-liposomal-epar-medicine-overview_fi.pdf)

svenska (SV) (141.89 KB - PDF)

**First published:**

10/12/2020

**Last updated:**

14/11/2022

[View](/sv/documents/overview/exparel-liposomal-epar-medicine-overview_sv.pdf)

Exparel liposomal : EPAR - Risk-management-plan summary

English (EN) (151.05 KB - PDF)

**First published:** 10/12/2020

[View](/en/documents/rmp-summary/exparel-liposomal-epar-risk-management-plan-summary_en.pdf)

## Product information

Exparel liposomal : EPAR - Product information

English (EN) (542.66 KB - PDF)

**First published:** 10/12/2020

**Last updated:** 13/08/2025

[View](/en/documents/product-information/exparel-liposomal-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-764)

български (BG) (716.76 KB - PDF)

**First published:**

10/12/2020

**Last updated:**

13/08/2025

[View](/bg/documents/product-information/exparel-liposomal-epar-product-information_bg.pdf)

español (ES) (579.42 KB - PDF)

**First published:**

10/12/2020

**Last updated:**

13/08/2025

[View](/es/documents/product-information/exparel-liposomal-epar-product-information_es.pdf)

čeština (CS) (525.49 KB - PDF)

**First published:**

10/12/2020

**Last updated:**

13/08/2025

[View](/cs/documents/product-information/exparel-liposomal-epar-product-information_cs.pdf)

dansk (DA) (599.53 KB - PDF)

**First published:**

10/12/2020

**Last updated:**

13/08/2025

[View](/da/documents/product-information/exparel-liposomal-epar-product-information_da.pdf)

Deutsch (DE) (588.01 KB - PDF)

**First published:**

10/12/2020

**Last updated:**

13/08/2025

[View](/de/documents/product-information/exparel-liposomal-epar-product-information_de.pdf)

eesti keel (ET) (470.75 KB - PDF)

**First published:**

10/12/2020

**Last updated:**

13/08/2025

[View](/et/documents/product-information/exparel-liposomal-epar-product-information_et.pdf)

ελληνικά (EL) (576.08 KB - PDF)

**First published:**

10/12/2020

**Last updated:**

13/08/2025

[View](/el/documents/product-information/exparel-liposomal-epar-product-information_el.pdf)

français (FR) (616.76 KB - PDF)

**First published:**

10/12/2020

**Last updated:**

13/08/2025

[View](/fr/documents/product-information/exparel-liposomal-epar-product-information_fr.pdf)

hrvatski (HR) (632.79 KB - PDF)

**First published:**

10/12/2020

**Last updated:**

13/08/2025

[View](/hr/documents/product-information/exparel-liposomal-epar-product-information_hr.pdf)

íslenska (IS) (554.36 KB - PDF)

**First published:**

10/12/2020

**Last updated:**

13/08/2025

[View](/is/documents/product-information/exparel-liposomal-epar-product-information_is.pdf)

italiano (IT) (575.83 KB - PDF)

**First published:**

10/12/2020

**Last updated:**

13/08/2025

[View](/it/documents/product-information/exparel-liposomal-epar-product-information_it.pdf)

latviešu valoda (LV) (616.06 KB - PDF)

**First published:**

10/12/2020

**Last updated:**

13/08/2025

[View](/lv/documents/product-information/exparel-liposomal-epar-product-information_lv.pdf)

lietuvių kalba (LT) (530.36 KB - PDF)

**First published:**

10/12/2020

**Last updated:**

13/08/2025

[View](/lt/documents/product-information/exparel-liposomal-epar-product-information_lt.pdf)

magyar (HU) (557.6 KB - PDF)

**First published:**

10/12/2020

**Last updated:**

13/08/2025

[View](/hu/documents/product-information/exparel-liposomal-epar-product-information_hu.pdf)

Malti (MT) (692.07 KB - PDF)

**First published:**

10/12/2020

**Last updated:**

13/08/2025

[View](/mt/documents/product-information/exparel-liposomal-epar-product-information_mt.pdf)

Nederlands (NL) (444.99 KB - PDF)

**First published:**

10/12/2020

**Last updated:**

13/08/2025

[View](/nl/documents/product-information/exparel-liposomal-epar-product-information_nl.pdf)

norsk (NO) (546.77 KB - PDF)

**First published:**

10/12/2020

**Last updated:**

13/08/2025

[View](/no/documents/product-information/exparel-liposomal-epar-product-information_no.pdf)

polski (PL) (687.05 KB - PDF)

**First published:**

10/12/2020

**Last updated:**

13/08/2025

[View](/pl/documents/product-information/exparel-liposomal-epar-product-information_pl.pdf)

português (PT) (577.04 KB - PDF)

**First published:**

10/12/2020

**Last updated:**

13/08/2025

[View](/pt/documents/product-information/exparel-liposomal-epar-product-information_pt.pdf)

română (RO) (669.88 KB - PDF)

**First published:**

10/12/2020

**Last updated:**

13/08/2025

[View](/ro/documents/product-information/exparel-liposomal-epar-product-information_ro.pdf)

slovenčina (SK) (665.03 KB - PDF)

**First published:**

10/12/2020

**Last updated:**

13/08/2025

[View](/sk/documents/product-information/exparel-liposomal-epar-product-information_sk.pdf)

slovenščina (SL) (646.81 KB - PDF)

**First published:**

10/12/2020

**Last updated:**

13/08/2025

[View](/sl/documents/product-information/exparel-liposomal-epar-product-information_sl.pdf)

Suomi (FI) (516.94 KB - PDF)

**First published:**

10/12/2020

**Last updated:**

13/08/2025

[View](/fi/documents/product-information/exparel-liposomal-epar-product-information_fi.pdf)

svenska (SV) (562.08 KB - PDF)

**First published:**

10/12/2020

**Last updated:**

13/08/2025

[View](/sv/documents/product-information/exparel-liposomal-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** R/0000248989 23/07/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Exparel liposomal : EPAR - All authorised presentations

English (EN) (60.16 KB - PDF)

**First published:** 10/12/2020

[View](/en/documents/all-authorised-presentations/exparel-liposomal-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-406)

български (BG) (72.16 KB - PDF)

**First published:**

10/12/2020

[View](/bg/documents/all-authorised-presentations/exparel-liposomal-epar-all-authorised-presentations_bg.pdf)

español (ES) (59.34 KB - PDF)

**First published:**

10/12/2020

[View](/es/documents/all-authorised-presentations/exparel-liposomal-epar-all-authorised-presentations_es.pdf)

čeština (CS) (80.87 KB - PDF)

**First published:**

10/12/2020

[View](/cs/documents/all-authorised-presentations/exparel-liposomal-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (62.06 KB - PDF)

**First published:**

10/12/2020

[View](/da/documents/all-authorised-presentations/exparel-liposomal-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (64.57 KB - PDF)

**First published:**

10/12/2020

[View](/de/documents/all-authorised-presentations/exparel-liposomal-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (61.78 KB - PDF)

**First published:**

10/12/2020

[View](/et/documents/all-authorised-presentations/exparel-liposomal-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (115.83 KB - PDF)

**First published:**

10/12/2020

[View](/el/documents/all-authorised-presentations/exparel-liposomal-epar-all-authorised-presentations_el.pdf)

français (FR) (55.86 KB - PDF)

**First published:**

10/12/2020

[View](/fr/documents/all-authorised-presentations/exparel-liposomal-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (82.08 KB - PDF)

**First published:**

10/12/2020

[View](/hr/documents/all-authorised-presentations/exparel-liposomal-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (62.2 KB - PDF)

**First published:**

10/12/2020

[View](/is/documents/all-authorised-presentations/exparel-liposomal-epar-all-authorised-presentations_is.pdf)

italiano (IT) (61.1 KB - PDF)

**First published:**

10/12/2020

[View](/it/documents/all-authorised-presentations/exparel-liposomal-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (80.45 KB - PDF)

**First published:**

10/12/2020

[View](/lv/documents/all-authorised-presentations/exparel-liposomal-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (81.41 KB - PDF)

**First published:**

10/12/2020

[View](/lt/documents/all-authorised-presentations/exparel-liposomal-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (70.24 KB - PDF)

**First published:**

10/12/2020

[View](/hu/documents/all-authorised-presentations/exparel-liposomal-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (84.81 KB - PDF)

**First published:**

10/12/2020

[View](/mt/documents/all-authorised-presentations/exparel-liposomal-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (61.51 KB - PDF)

**First published:**

10/12/2020

[View](/nl/documents/all-authorised-presentations/exparel-liposomal-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (62.29 KB - PDF)

**First published:**

10/12/2020

[View](/no/documents/all-authorised-presentations/exparel-liposomal-epar-all-authorised-presentations_no.pdf)

polski (PL) (84.08 KB - PDF)

**First published:**

10/12/2020

[View](/pl/documents/all-authorised-presentations/exparel-liposomal-epar-all-authorised-presentations_pl.pdf)

português (PT) (64.38 KB - PDF)

**First published:**

10/12/2020

[View](/pt/documents/all-authorised-presentations/exparel-liposomal-epar-all-authorised-presentations_pt.pdf)

română (RO) (79.73 KB - PDF)

**First published:**

10/12/2020

[View](/ro/documents/all-authorised-presentations/exparel-liposomal-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (79.72 KB - PDF)

**First published:**

10/12/2020

[View](/sk/documents/all-authorised-presentations/exparel-liposomal-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (81.46 KB - PDF)

**First published:**

10/12/2020

[View](/sl/documents/all-authorised-presentations/exparel-liposomal-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (61.25 KB - PDF)

**First published:**

10/12/2020

[View](/fi/documents/all-authorised-presentations/exparel-liposomal-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (61.16 KB - PDF)

**First published:**

10/12/2020

[View](/sv/documents/all-authorised-presentations/exparel-liposomal-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Exparel liposomal Active substance bupivacaine International non-proprietary name (INN) or common name bupivacaine Therapeutic area (MeSH) Acute Pain Anatomical therapeutic chemical (ATC) code N01BB01

### Pharmacotherapeutic group

- Amides
- Anesthetics, local

### Therapeutic indication

Exparel liposomal is indicated:

- in adults as a brachial plexus block or femoral nerve block for treatment of post-operative pain.
- in adults and children aged 6 years or older as a field block for treatment of somatic post-operative pain from small- to medium-sized surgical wounds.

## Authorisation details

EMA product number EMEA/H/C/004586 Marketing authorisation holder

Pacira Ireland Limited

Pacira Ireland Limited

Opinion adopted 17/09/2020 Marketing authorisation issued 16/11/2020 Revision 2

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Exparel liposomal : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (144.57 KB - PDF)

**First published:** 13/08/2025

[View](/en/documents/procedural-steps-after/exparel-liposomal-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Exparel liposomal : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (165.31 KB - PDF)

**First published:** 14/11/2022

**Last updated:** 13/08/2025

[View](/en/documents/procedural-steps-after/exparel-liposomal-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Exparel liposomal-H-C-4586-II-0005: EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/CHMP/794139/2022

English (EN) (8.2 MB - PDF)

**First published:** 14/11/2022

[View](/en/documents/variation-report/exparel-liposomal-h-c-4586-ii-0005-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of opinion for Exparel liposomal

Adopted

Reference Number: EMA/CHMP/762558/2022

English (EN) (131.47 KB - PDF)

**First published:** 16/09/2022

[View](/en/documents/smop/chmp-post-authorisation-summary-opinion-exparel-liposomal_en.pdf)

## Initial marketing authorisation documents

Exparel liposomal : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/528272/2020

English (EN) (2.69 MB - PDF)

**First published:** 10/12/2020

[View](/en/documents/assessment-report/exparel-liposomal-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Exparel

Adopted

Reference Number: EMA/CHMP/476199/2020

English (EN) (120.64 KB - PDF)

**First published:** 18/09/2020

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-exparel_en.pdf)

#### News on Exparel liposomal

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 September 2022](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-september-2022) 16/09/2022

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 September 2020](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-14-17-september-2020) 18/09/2020

#### More information on Exparel liposomal

- [EMEA-000877-PIP03-17-M05 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-000877-pip03-17-m05)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 13/08/2025

## Share this page

[Back to top](#main-content)